TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Xvivo Perfusion AB ( (SE:XVIVO) ) just unveiled an update.
XVIVO Perfusion AB reported a slight decline in net sales for the first nine months of 2025, with a 1% organic growth in local currencies. The company saw significant growth in its Abdominal business area, while the Thoracic segment experienced a decline, impacting overall performance. Despite this, the company maintained a strong gross margin of 74%, and continued to invest heavily in research and development, which affected its net profit and cash flow.
The most recent analyst rating on (SE:XVIVO) stock is a Hold with a SEK188.00 price target. To see the full list of analyst forecasts on Xvivo Perfusion AB stock, see the SE:XVIVO Stock Forecast page.
More about Xvivo Perfusion AB
XVIVO Perfusion AB is a company operating in the medical technology industry, primarily focusing on organ preservation and transplantation solutions. The company offers a range of products and services aimed at improving the viability and success rates of organ transplants, with a market focus on thoracic and abdominal organ systems.
Average Trading Volume: 182,281
Technical Sentiment Signal: Sell
Current Market Cap: SEK5.66B
For an in-depth examination of XVIVO stock, go to TipRanks’ Overview page.